DEVELOPMENT AND VALIDATION OF A STABILITY-INDICATING ISOCRATIC REVERSE PHASE-LIQUID CHROMATOGRAPHY ASSAY FOR DETERMINATION OF PHENYTOIN IN BULK AND PHARMACEUTICAL FORMULATIONS
Objective: To develop and validate a stability-indicating reversed phase high performance liquid chromatography (RP-HPLC) assay for the determination of phenytoin in bulk and pharmaceutical dosage forms.
Methods: A HPLC instrument incorporating aZorbaxC-18 analytical column (250x4.6 mm, 5Î¼m particles) with a mobile phase comprising acetonitrile: water in the ratio 50:50 (%v/v) was employed for the determination of phenytoin. The flow rate was set with an isocratic program, the temperature of the column was maintained at 25 Â°C and a detection wavelength of 200 nm was employed using an ultraviolet detector. The method was validated as per The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) guidelines.
Results: Total chromatographic analysis time per sample was 6 min with phenytoin eluting with the reaction time of 4.6Â±0.2 min. Phenytoin was exposed to acidic, basic, oxidative, photolytic and thermal stress conditions and the specificity of the assay was confirmed. The calibration plot was linear(R2â‰¥0.999) over the phenytoin concentration range 5.0-100.0Î¼g/ml. The percentage means recoveries were found to be in the range of 98-102%. The relative standard deviation of precision and robustness were within prescribed limits (<2%). The limit of detection was 0.047 Âµg/ml while the limit of quantitation was established as 0.143 Âµg/ml.
Conclusion: A simple, accurate, precise and stability-indicating RP-HPLC assay was successfully developed for the determination of phenytoin in bulk and dosage forms. Hence, this assay is useful for the analysis of phenytoin in formulations in medicines development and pharmaceutical manufacturing setting.
2. Darwish IA, Ei-Massik MA, Hassan EE, Ei-Khordagui LK. Assessment of a hydroalcoholic surfactant solution as a medium for the dissolution testing of phenytoin. Int J Pharm 1996;140:25-32.
3. Sohrevardi SM, Nejad MA. Enteral nutrition and phenytoin administration in head trauma patients. Tanaffos 2008;7(3):59-62.
4. Porojan D, Baldea I, Achim M, Cosgarea R. Phenytoin induces in vitro melanocyte proliferation. Int J Dermatol 2012;51:1379-84.
5. Talas G, Brown RA, McGrouther A. Role of phenytoin in wound healingâ€“a wound pharmacology perspective. Biochem Pharmacol 1999;57:1085-94.
6. Shaw J, Hughes CM, Lagan KM, Bell PM. The clinical effect of topical phenytoin on wound healing: a systematic review. Br J Dermatol 2007;157:997-1004.
7. Hokkam E, EI-Labban G, Shams M, Rifaat S, EI-Mezaien M. The use of topical phenytoin for healing of chronic venous ulcerations. Int J Surg 2011;9:335-8.
8. Aboul-Enein HY, Serignese V. Thin layer chromatographic (TLC) determination of phenytoin in pharmaceutical formulations and identification of its hydroxylated urinary metabolites. Anal Lett 1994;27(4):723-9.
9. Roy SMN, Yetal SM, Vaidya VV, Joshi SS. Determination and quantification of phenytoin in human plasma by liquid chromatography with electrospray ionization tandem mass spectrometry. J Chem 2008;5(1):169-76.
10. Walash MI, Rizk MS, Sheribah ZA, Salim MM. Derivative spectrophotometric analysis of benzophenone (as an impurity) in phenytoin. Chem Cent J 2011;5:1-10.
11. Castro A, Ibanez J, DiCesare JL, Adams RF, Malkus H. Comparative determination of phenytoin by spectrophotometry, gas chromatography, liquid chromatography, enzyme immunoassay, and radioimmunoassay. Clin Chem 1978;24(4):710-3.
12. Khedr A, Moustafa M, Abdel-Naim AB, Alahdal A, Mosli H. High-performance liquid chromatographic method for determination of phenytoin in rabbits receiving sildenafil. Anal Chem Insights 2008;3:61-7.
13. Lin PC, Hsieh YH, Liao FF, Chen SH. Determination of free and total levels of phenytoin in human plasma from patients with epilepsy by MEKC: an adequate alternative to HPLC. Electrophoresis 2010;31:1572-82.
14. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. Validation of analytical procedures: Definitions and Terminology ICH Q2A; 1995.
15. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. Validation of analytical procedures: Methodology ICH Q2B; 1997.
16. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. Validation of analytical procedures: Text and Methodology ICH Q2(R1); 2005.
17. Sivakumar T, Manavalan R, Valliappan K. Development and validation of a reversed-phase HPLC method for simultaneous determination of domperidone and pantoprazole in pharmaceutical dosage forms. Acta Chromatogr 2007;18:130-42.